Elsayed Z Soliman1, Amit J Shah2, Andrew Boerkircher2, Yabing Li2, Pentti M Rautaharju2. 1. From the Division of Public Health Sciences, Department of Epidemiology and Prevention, Epidemiological Cardiology Research Center (EPICARE) (E.Z.S., Y.L., P.M.R.) and Section on Cardiology, Department of Internal Medicine (E.Z.S.), Wake Forest School of Medicine, Winston Salem, NC; Department of Epidemiology, Emory University, Atlanta, GA (A.J.S.); and Department of Internal Medicine, Wake Forest Baptist Medical Center, Winston Salem, NC (A.B.). esoliman@wakehealth.edu. 2. From the Division of Public Health Sciences, Department of Epidemiology and Prevention, Epidemiological Cardiology Research Center (EPICARE) (E.Z.S., Y.L., P.M.R.) and Section on Cardiology, Department of Internal Medicine (E.Z.S.), Wake Forest School of Medicine, Winston Salem, NC; Department of Epidemiology, Emory University, Atlanta, GA (A.J.S.); and Department of Internal Medicine, Wake Forest Baptist Medical Center, Winston Salem, NC (A.B.).
Abstract
BACKGROUND: Prolonged-QT commonly coexists in the ECG with left ventricular hypertrophy (ECG-LVH). However, it is unclear whether to what extent QT prolongation coexisting with ECG-LVH can explain the prognostic significance of ECG-LVH, and whether prolonged-QT coexisting with ECG-LVH should be considered as an innocent consequence of ECG-LVH. METHODS AND RESULTS: The study population consisted of 7506 participants (mean age, 59.4±13.3 years; 49% whites; and 47% men) from the US Third National Health and Nutrition Examination Survey. ECG-LVH was defined by Cornell voltage criteria. Prolonged heart-rate-adjusted QT (prolonged-QTa) was defined as QTa≥460 ms in women or 450 ms in men. Cox proportional hazards analysis was used to calculate the hazard ratios with 95% confidence intervals for the risk of all-cause mortality for various combinations of ECG-LVH and prolonged-QTa. ECG-LVH was present in 4.2% (N=312) of the participants, of whom 16.4% had prolonged-QTa. In a multivariable-adjusted model and compared with the group without ECG-LVH or prolonged-QTa, mortality risk was highest in the group with concomitant ECG-LVH and prolonged-QTa (hazard ratio, 1.63; 95% confidence interval, 1.12-2.36), followed by isolated ECG-LVH (1.48; 1.24-1.77), and then isolated prolonged-QTa (1.27; 1.12-1.46). In models with similar adjustment where ECG-LVH and prolonged-QTa were entered as 2 separate variables and subsequently additionally adjusted for each other, the mortality risk was essentially unchanged for both variables. CONCLUSIONS: Although prolonged-QT commonly coexists with LVH, both are independent markers of poor prognosis. Concomitant presence of prolonged-QT and ECG-LVH carries a higher risk than either predictor alone.
BACKGROUND: Prolonged-QT commonly coexists in the ECG with left ventricular hypertrophy (ECG-LVH). However, it is unclear whether to what extent QT prolongation coexisting with ECG-LVH can explain the prognostic significance of ECG-LVH, and whether prolonged-QT coexisting with ECG-LVH should be considered as an innocent consequence of ECG-LVH. METHODS AND RESULTS: The study population consisted of 7506 participants (mean age, 59.4±13.3 years; 49% whites; and 47% men) from the US Third National Health and Nutrition Examination Survey. ECG-LVH was defined by Cornell voltage criteria. Prolonged heart-rate-adjusted QT (prolonged-QTa) was defined as QTa≥460 ms in women or 450 ms in men. Cox proportional hazards analysis was used to calculate the hazard ratios with 95% confidence intervals for the risk of all-cause mortality for various combinations of ECG-LVH and prolonged-QTa. ECG-LVH was present in 4.2% (N=312) of the participants, of whom 16.4% had prolonged-QTa. In a multivariable-adjusted model and compared with the group without ECG-LVH or prolonged-QTa, mortality risk was highest in the group with concomitant ECG-LVH and prolonged-QTa (hazard ratio, 1.63; 95% confidence interval, 1.12-2.36), followed by isolated ECG-LVH (1.48; 1.24-1.77), and then isolated prolonged-QTa (1.27; 1.12-1.46). In models with similar adjustment where ECG-LVH and prolonged-QTa were entered as 2 separate variables and subsequently additionally adjusted for each other, the mortality risk was essentially unchanged for both variables. CONCLUSIONS: Although prolonged-QT commonly coexists with LVH, both are independent markers of poor prognosis. Concomitant presence of prolonged-QT and ECG-LVH carries a higher risk than either predictor alone.
Authors: S G Priori; E Aliot; C Blomstrom-Lundqvist; L Bossaert; G Breithardt; P Brugada; A J Camm; R Cappato; S M Cobbe; C Di Mario; B J Maron; W J McKenna; A K Pedersen; U Ravens; P J Schwartz; M Trusz-Gluza; P Vardas; H J Wellens; D P Zipes Journal: Eur Heart J Date: 2001-08 Impact factor: 29.983
Authors: L Oikarinen; M S Nieminen; M Viitasalo; L Toivonen; K Wachtell; V Papademetriou; S Jern; B Dahlöf; R B Devereux; P M Okin Journal: J Hypertens Date: 2001-10 Impact factor: 4.844
Authors: Jacqueline M Dekker; Richard S Crow; Peter J Hannan; Evert G Schouten; Aaron R Folsom Journal: J Am Coll Cardiol Date: 2004-02-18 Impact factor: 24.094
Authors: Lasse Oikarinen; Markku S Nieminen; Matti Viitasalo; Lauri Toivonen; Sverker Jern; Björn Dahlöf; Richard B Devereux; Peter M Okin Journal: Hypertension Date: 2004-03-22 Impact factor: 10.190
Authors: Nikhil Patel; Wesley T O'Neal; S Patrick Whalen; Elsayed Z Soliman Journal: Ann Noninvasive Electrocardiol Date: 2017-06-29 Impact factor: 1.468
Authors: Wesley T O'Neal; Virginia J Howard; Dawn Kleindorfer; Brett Kissela; Suzanne E Judd; Leslie A McClure; Mary Cushman; George Howard; Elsayed Z Soliman Journal: Europace Date: 2015-10-20 Impact factor: 5.214
Authors: Amit J Shah; Viola Vaccarino; A Cecile J W Janssens; W Dana Flanders; Suman Kundu; Emir Veledar; Peter W F Wilson; Elsayed Z Soliman Journal: JAMA Cardiol Date: 2016-10-01 Impact factor: 14.676
Authors: Wesley T O'Neal; Jimmy T Efird; Hooman Kamel; Saman Nazarian; Alvaro Alonso; Susan R Heckbert; W T Longstreth; Elsayed Z Soliman Journal: Clin Res Cardiol Date: 2015-03-10 Impact factor: 5.460
Authors: Enrico G Ferro; Shafika Abrahams-Gessel; Thiago Veiga Jardim; Ryan Wagner; F Xavier Gomez-Olive; Alisha N Wade; Ferande Peters; Stephen Tollman; Thomas A Gaziano Journal: Circ Cardiovasc Qual Outcomes Date: 2021-11-16
Authors: Chaudry N Majeed; Muhammad I Ahmad; Irfan Ahsan; Muhammad A Anees; Sanjay K Maheshwari; Elsayed Z Soliman Journal: Ann Noninvasive Electrocardiol Date: 2019-09-09 Impact factor: 1.468
Authors: Katherine C Wu; Long Zhang; Sabina A Haberlen; Hiroshi Ashikaga; Todd T Brown; Matthew J Budoff; Gypsyamber D'Souza; Lawrence A Kingsley; Frank J Palella; Joseph B Margolick; Otoniel Martínez-Maza; Elsayed Z Soliman; Wendy S Post Journal: Heart Date: 2018-10-26 Impact factor: 5.994
Authors: Nikmah S Idris; Michael M H Cheung; Diederick E Grobbee; David Burgner; Nia Kurniati; Mulyadi M Djer; Cuno S P M Uiterwaal Journal: Open Heart Date: 2016-03-10